Skip to main content
SpringerLink
Log in

Kinetic Concepts in the Treatment of Breast Cancer

  • Conference paper
Adjuvant Therapy of Breast Cancer IV

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 127))

Abstract

A great puzzle of modem medical oncology is why the survival times of patients with advanced breast cancer have not improved significantly over several decades [1]. Although most patients’ tumors respond to modern high-dose chemotherapies, median survival times have advanced by mere months [2]. Indeed, prolongation of life to the length of a “natural”lifespan sans cancer is rarely achieved. Even ultrahigh-dose chemotherapy with autologous bone marrow reinfusion is of major benefit only to the unusual patient whose cancer is being exquisitely responsive to conventional chemotherapy [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Norton L (1991) Metastatic breast cancer - length and quality of life (editorial). N Engl J Med 325:1370–1371

    Article  PubMed  CAS  Google Scholar 

  2. Hryniuk WM (1988) The importance of dose intensity in the outcome of chemotherapy. In: DeVita VT Jr, Heilman S, Rosenberg SA (eds) Important Advances in Oncology 1988. Lippincott, Philadelphia, pp 121–141

    Google Scholar 

  3. Peters WP (1991) High dose chemotherapy and autologous bone marrow support for breast cancer. In: DeVita VT Jr, Heilman S, Rosenberg SA (eds) Important Advances in Oncology 1991. Lippincott, Philadelphia, pp 135–150

    Google Scholar 

  4. Skipper HE (1986) Laboratory models: the historical perspective. Cancer Treat Rep 70:3–7

    PubMed  CAS  Google Scholar 

  5. Skipper HE (1986) Analyses of multiarmed trials in which animals bearing different burdens of L1210 leukemia cells were treated with two, three, and four drug combinations delivered in different ways with varying dose intensities of each drug and varying average dose intensities. South Res Inst Booklet 7(42): 87–92

    Google Scholar 

  6. Luria SE, Delbruck M (1943) Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491

    PubMed  CAS  Google Scholar 

  7. Law LW (1952) Origin of resistance of leukaemic cells to folic acid antagonists. Nature 169:628–629

    Article  PubMed  CAS  Google Scholar 

  8. Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733

    PubMed  CAS  Google Scholar 

  9. Goldie JH (1987) Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Sem in Oncol 14:1–7

    CAS  Google Scholar 

  10. Goldie JH, Coldman AH (1986) Application of theoretical models to chemotherapy protocol design. Cancer Treat Rep 70:127–131

    PubMed  CAS  Google Scholar 

  11. DeVita VT Jr, Young RC, Canellos GP (1975) Combination vs. single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35:98–110

    Article  PubMed  Google Scholar 

  12. Ludwig Breast Cancer Study Group (1988) Combination adjuvant chemotherapy for node-positive breast cancer. N Engl J Med 319:677–683

    Article  Google Scholar 

  13. Perloff M, Norton L, Korzun A, Wood W, Carey R, Weinberg V, Holland JF (1986) Advantage of an adriamycin combination plus halotestin after initial CMFVP for adjuvant therapy of node-positive stage II breast cancer. Proc Am Soc Clin Oncol 70:273

    Google Scholar 

  14. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M (1991) Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134–2140

    PubMed  CAS  Google Scholar 

  15. Bonadonna G, Valagussa P, Zambetti M, Buzzoni R (1992) Sequential adriamycin-CMF in the adjuvant treatment of breast cancer with more than three positive axillary nodes. Proc Am Soc Clin Oncol 70

    Google Scholar 

  16. Kardinal CG, Perry MC, Korzun AH, Rice MA, Ginsberg S, Wood WC (1988) Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy: a subset analysis of CALGB study 8081. Cancer 61:415–419

    Article  PubMed  CAS  Google Scholar 

  17. Valagussa P, Tancini G, Bonadonna G (1986) Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58:1411–1417

    Article  PubMed  CAS  Google Scholar 

  18. Bloom H, Richardson M, Harris B (1962) Natural history of untreated breast cancer (1804–1933): comparison of treated and untreated cases according to histological grade of malignancy. BMJ 2:213–221

    Article  PubMed  CAS  Google Scholar 

  19. Early Breast Cancer Trialists Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–15, 71–85

    Google Scholar 

  20. Norton L (1988) A Gompertzian model of human breast cancer growth. Cancer Res 48:7067–7071

    PubMed  CAS  Google Scholar 

  21. Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and the design of treatment schedules. Cancer Treat Rep 61:1307–1317

    PubMed  CAS  Google Scholar 

  22. Norton L, Simon R (1986) The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163–169

    PubMed  CAS  Google Scholar 

  23. Norton L (1985) Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 12:231–249

    PubMed  CAS  Google Scholar 

  24. Hudis C, Lebwohl D, Crown J, Gilewski T, Surbone A, Hakes T, Reichman B, Seidman A, Harrison M, Bellettieri R, Hamilton N, Yao TJ, Weiselberg L, Moore A, Greenberg S, Norton L (1992) Feasibility of adjuvant dose-intensive cyclophosphamide with G-CSF after doxorubicin in women with high-risk stage ΙΙ/IΙΙ resectable breast cancer. Proc Am Soc Clin Oncol 48

    Google Scholar 

  25. Peters WP, Ross M, Vredenburgh J, Meisenberg B, Rosner G, Marks L, Mathias B, Henderson C, Hurd D, Budman D, Norton L, Weiss RB (1992) High-dose alkylating agents and autologous bone marrow support for stage II/III breast cancer including 10 or more axillary lymph nodes. Proc Am Soc Clin Oncol 59

    Google Scholar 

  26. Lippman ME, Dickson RB, Bates S, Knabbe C, Huff K, Swain S, McManaway M, Bronzert D, Kasid A, Gelman EP (1986) Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat 7:59–70

    Article  PubMed  CAS  Google Scholar 

  27. Lippman ME (1987) Hormonal stimulation and chemotherapy for breast cancer (editorial). J Clin Oncol 5:331–332

    PubMed  CAS  Google Scholar 

  28. Norton L (1990) Biology of residual breast cancer after therapy: A kinetic interpretation. In: Ragaz J, Simpson-Herren L, Lippman ME, Fisher B (eds) Effects of therapy on biology and kinetics of the residual tumor, part A: preclinical aspects. Wiley-Liss, New York, pp 109–132

    Google Scholar 

  29. Koury MJ, Bondurant MC (1990) Erythropoietin retards DNA breakdown and prevents programmed death in erythoid progenitor cells. Science 248:378–381

    Article  PubMed  CAS  Google Scholar 

  30. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR (1990) Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76–79

    Article  PubMed  CAS  Google Scholar 

  31. Barry MA, Behnke CA, Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplain, other anticancer drugs, toxins and gyperthermia. Biochem Pharmacol 40:2353–2362

    Article  PubMed  CAS  Google Scholar 

  32. Norton L, Baselga J, Masui H, Hyman J, Kumar R, Mendelsohn J (1991) Growth factor perturbation: a therapeutically exploitable mechanism for chemotherapy action. Proc Am Soc Clin Oncol 208

    Google Scholar 

  33. Baselga J, Norton L, Miller W, Masui H, Mendelsohn J (1992) Synergistic antitumor effects of adriamycin and anti-epidermal growth factor receptor meonclonal antibodies. Proc Am Soc Clin Oncol 238

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast and Gynecologic Cancer Medicine Service Memorial Sloan-Kettering Cancer Center, NY, USA

    L. Norton

Authors
  1. L. Norton
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine C, Kantonsspital, CH-9007, St. Gallen, Switzerland

    Hans-Jörg Senn  & Beat Thürlimann  & 

  2. Division of Biostatistics, Dana Farber Cancer Institute, 44, Binney Street, Boston, MA, 02115, USA

    Richard D. Gelber Ph.D.

  3. Ospedale Civico, CH-6900, Lugano, Switzerland

    Aron Goldhirsch

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Norton, L. (1993). Kinetic Concepts in the Treatment of Breast Cancer. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Breast Cancer IV. Recent Results in Cancer Research, vol 127. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84745-5_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-84745-5_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-84747-9

  • Online ISBN: 978-3-642-84745-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation